Continuous Release of Interleukin-2 from Liposomal IL-2 (Mixture of Interleukin-2 and Liposomes) After Subcutaneous Administration to Mice
- 1 January 2003
- journal article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 29 (10) , 1149-1153
- https://doi.org/10.1081/ddc-120025872
Abstract
Recombinant interleukin-2 (IL-2) was strongly and almost completely adsorbed onto small and hydrophobic liposomes by simple mixing under optimal conditions (liposome: DSPC-DSPG; molar ratio, 10:1; 30-50 nm in size, ratio of IL-2 to liposome: 4.0 JRU/nmol lipid). This liposomal IL-2 displayed better distribution after intravenous administration in mice and improved therapeutic effect against experimental M5076 metastases, as reported previously. In this study, the elimination of IL-2 from the dosing area was investigated when the liposomal IL-2 was administered to mice subcutaneously. The results suggest that the release of IL-2 from this liposome was continuous and almost complete. The mean residence time (MRT) of IL-2 in the dosing area was 11.0 +/- 1.65 hr. This resulted in the 8-fold times enhancement of MRT in the systemic circulation by the presence of liposomes, and IL-2 was detected in the serum for 2 days. Using this liposomal IL-2 is expected to have the potential to decrease the number of injections and enhance the efficacy of IL-2 in immunotherapies and therapies against tumor.Keywords
This publication has 12 references indexed in Scilit:
- A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture)Journal of Controlled Release, 2002
- A novel and simple type of liposome carrier for recombinant interleukin-2Journal of Pharmacy and Pharmacology, 2001
- Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancerAnnals of Oncology, 1999
- Stabilization of aerosolized IFN-γ by liposomesInternational Journal of Pharmaceutics, 1999
- Effective cancer therapy with a single injection of interleukin-2 at the site of the tumourCancer Immunology, Immunotherapy, 1999
- Blood Concentrations of Tumor Necrosis Factor-Alpha in Malignant Lymphomas and Their Decrease as a Predictor of Disease Control in Response to Low-Dose Subcutaneous Immunotherapy with Interleukin-2The International Journal of Biological Markers, 1999
- Low‐dose subcutaneous interleukin‐2 in patients with minimal residual lymphoid neoplasm diseaseEuropean Journal of Haematology, 1999
- Immunotherapy for colorectal cancerThe American Journal of Surgery, 1999
- Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot TrialAnnals of Surgical Oncology, 1999
- Section Review: Biologicals & Immunologicals: Immunotherapy with interleukin-2: Recent developmentsExpert Opinion on Investigational Drugs, 1996